Standard BioTools Inc. Proceeds from Issuance of Secured Debt
Standard BioTools Inc. (LAB) reported Proceeds from Issuance of Secured Debt of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSecuredDebt · last filed 2023-03-14
- Standard BioTools Inc. proceeds from issuance of secured debt for the quarter ending 2022-12-31 was $0.00.
- Standard BioTools Inc. proceeds from issuance of secured debt for the quarter ending 2021-12-31 was $0.00.
- Standard BioTools Inc. proceeds from issuance of secured debt for the quarter ending 2020-12-31 was $0.00.
- Standard BioTools Inc. proceeds from issuance of secured debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Standard BioTools Inc. proceeds from issuance of secured debt for fiscal 2021 was $10.00M.
- Standard BioTools Inc. proceeds from issuance of secured debt for fiscal 2020 was $0.00.
- Standard BioTools Inc. proceeds from issuance of secured debt for fiscal 2019 was $0.00.
| Period end | Proceeds from Issuance of Secured Debt 3 month | Proceeds from Issuance of Secured Debt 9 month | Proceeds from Issuance of Secured Debt 12 month |
|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $0.00 10-K · filed 2023-03-14 | |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-09 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $10.00M 10-K · filed 2023-03-14 | |
| 2021-09-30 | $10.00M 10-Q · filed 2022-11-09 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $0.00 10-K · filed 2022-03-08 | |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-09 | ||
| 2019-12-31 | $0.00 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |